EXAS - Exact Sciences Price to Earnings Adjusted for Growth Rate

Stable demand for cancer screening provides Exact Sciences (EXAS) with steady revenue. After applying the undervalued "rockets" PEG filter on GURU.Markets, we find a value of 0.00, representing the current metric. Routine Cologuard prescriptions form the business foundation, turning tests into a predictable cash cow, while high loyalty among leading bioinformaticians and oncologists eliminates any shortage of key competencies.

Cologuard (EXAS): PEG Multiple from 07/04/2022 to 04/04/2026

Analytical breakdowns for Exact Sciences (EXAS)

- current price and projected stock value:

Price Chart Exact Sciences Corp|EXAS - Consensus Target

- market capitalization statistics:

Market Value Cologuard|EXAS - Total Company Value

- shareholders' equity book value data:

Net Assets per Share Exact Sciences|EXAS - Book Capitalization|Market Capitalization to Book Value exactsciences.com|EXAS - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

EXAS - Net Income|Future Net Profit Exact Sciences|EXAS - Price to Earnings Ratio|Future Price to Earnings Multiple Exact Sciences Inc.|EXAS - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Cologuard|EXAS - Operating profit EBITDA|Net earnings per share for the last 12 months Exact Sciences|EXAS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months exactsciences.com|EXAS - Earnings growth in current year|Expected net earnings per share growth next year Exact Sciences

Summary company analytics:Exact Sciences Corp (EXAS)

Steady demand for vital cancer screening provides Exact Sciences (EXAS) with a defensive profile, making an analysis through the PEG ratio filter particularly representative. This ratio correlates the P/E multiple with earnings growth rates, allowing an investor to determine whether the market price justifies the actual business development dynamics or if the asset is undervalued relative to its growth potential.

Competing companies